193400-52-1

Usage

Uses

Used in Pharmaceutical Industry:
Thieno[2,3-b]pyridine-2-carboxylic acid, 3-aMino-6-Methyl-, Methyl ester is used as a key intermediate in the synthesis of various drugs for [application reason]. Its unique structure and properties make it a valuable building block for the development of new pharmaceuticals with potential therapeutic benefits.
Used in Drug Discovery and Development:
In the field of drug discovery and development, Thieno[2,3-b]pyridine-2-carboxylic acid, 3-aMino-6-Methyl-, Methyl ester is used as a starting material for the design and synthesis of novel compounds with potential medicinal properties. Its heterocyclic nature and functional groups provide a versatile platform for chemical modifications and optimization, leading to the discovery of new drug candidates with improved efficacy and selectivity.
Used in Medicinal Chemistry Research:
Thieno[2,3-b]pyridine-2-carboxylic acid, 3-aMino-6-Methyl-, Methyl ester is utilized as a research tool in medicinal chemistry to explore the structure-activity relationships of heterocyclic compounds. Its unique features and reactivity enable chemists to investigate the impact of various structural modifications on the biological activity and pharmacokinetic properties of the resulting compounds, ultimately contributing to the advancement of drug discovery efforts.

Upstream product

• 28900-10-9 2-chloro-6-methylnicotinonitrile 
• 2365-48-2 Methyl thioglycolate 
• 4241-27-4 1,2-dihydro-6-methyl-2-oxo-3-pyridinecarbonitrile 

Downstream Products

• 1644599-80-3 methyl 6-methyl-3-(4-phenyl-1H-1,2,3-triazol-1-yl)thieno[2,3-b]pyridine-2-carboxylate 
• 1427420-74-3 C₁₉H₂₀N₂O₅S 

Relevant academic research and scientific papers

Polysubstituted thieno[2,3-b]pyridine derivatives, and preparation method and application thereof

The invention discloses polysubstituted thieno[2,3-b]pyridine derivatives, and a preparation method and an application thereof. The structural formula of the derivatives are represented by formula I shown in the description. A compound for inhibiting a urea transporter is screened by using an erythrocyte model. Experimental results show that the compounds (represented by formula I-1) can inhibit the permeation of a urea transporter UT-B mediated erythrocyte membrane to urea, and the effect of the compounds has a dose-dependent relationship; the compounds represented by the formula I-1 have nocytotoxic effect on MDCK cells within an effective dose range, so the effect of the compounds represented by the formula I-1 on inhibiting cell permeation urea is irrelevant to the cytotoxicity of thecompounds; the inhibition effect of the compounds represented by the formula I-1 on the urea transporter UT-B is gradually enhanced; the inhibiting effect of the compounds represented by the formulaI-1 on the UT-B is reversible; and in-vivo test results show that the compounds represented by the formula I-1 can significantly increase the urination volume of rats, reduce the concentration of ureain rat urine and reduce the osmotic pressure, so that the compounds represented by the formula I-1 generate a urea selective diuresis effect in vivo.

Discovery and optimization of thienopyridine derivatives as novel urea transporter inhibitors

Urea transporters (UTs) play an important role in the urine concentrating mechanism and are recognized as novel targets for developing small molecule inhibitors with salt-sparing diuretic activity. Thienoquinoline derivatives, a class of novel UT-B inhibitors identified by our group, play a significant diuresis in animal model. However, the poor solubility and low bioavailability limited its further development. To overcome these shortcomings, the structure modification of thienoquinoline was carried out in this study, which led to the discovery of novel thienopyridine derivatives as specific urea transporter inhibitors. Further optimization obtained the promising preclinical candidate 8n with not only excellent inhibition effect on urea transporters and diuretic activity on rat model, but also suitable water solubility and Log P value.

Synthesis of methyl 3-azidothieno[2,3-b]pyridine-2-carboxylates and application of the huisgen reaction

The preparation of new substituted methyl 3-azidothieno[2,3-b]pyridine carboxylates by azotization of methyl 3-aminothieno[2,3-b]pyridine and subsequent treatment with sodium azide is described. Via Huisgen's 1,3-dipolar cycloaddition between substituted alkynes and the prepared azides, methyl 1,2,3-triazolo-thieno[2,3-b]pyridine carboxylates have been obtained.

Synthesis and biological evaluation of 2-(alkoxycarbonyl)-3-anilinobenzo[b] thiophenes and thieno[2,3-b]pyridines as new potent anticancer agents

Two new series of inhibitors of tubulin polymerization based on the 2-(alkoxycarbonyl)-3-(3′,4′,5′-trimethoxyanilino)benzo[b] thiophene and thieno[2,3-b]pyridine molecular skeletons were synthesized and evaluated for antiproliferative activity on a panel

Pyrido-fused thienyl- and furanyl-oxazolidinones

The present invention relates to new pyrido-fused thienyl- and furanyl-oxazolidinones, processes for their preparation and their use as medicaments, in particular as antibacterial medicaments.